In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The closing price of Ginkgo Bioworks Holdings Inc (NYSE: DNA) was $7.93 for the day, up 3.39% from the previous closing price of $7.67. In other words, the price has increased by $3.39 from its previous closing price. On the day, 0.82 million shares were traded.
Ratios:
Our analysis of DNA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.88 and its Current Ratio is at 4.88. In the meantime, Its Debt-to-Equity ratio is 0.67 whereas as Long-Term Debt/Eq ratio is at 0.67.
Raymond James Downgraded its Outperform to Mkt Perform on November 14, 2023, whereas the target price for the stock was revised from $3.50 to $2.50.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 16 ’25 when Che Austin bought 99 shares for $7.72 per share.
Che Austin bought 99 shares of DNA for $765 on May 15 ’25. On May 14 ’25, another insider, Che Austin, who serves as the Officer of the company, bought 99 shares for $8.01 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 1.96 while its Price-to-Book (P/B) ratio in mrq is 0.63.
Stock Price History:
Over the past 52 weeks, DNA has reached a high of $34.78, while it has fallen to a 52-week low of $5.00. The 50-Day Moving Average of the stock is 10.33%, while the 200-Day Moving Average is calculated to be -10.31%.
Shares Statistics:
A total of 43.08M shares are outstanding, with a floating share count of 37.41M. Insiders hold about 32.63% of the company’s shares, while institutions hold 57.94% stake in the company.
Earnings Estimates
The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 5 analysts. It ranges from a high estimate of $44M to a low estimate of $38.19M. As of the current estimate, Ginkgo Bioworks Holdings Inc’s year-ago sales were $56.21MFor the next quarter, 5 analysts are estimating revenue of $43.79M. There is a high estimate of $45.85M for the next quarter, whereas the lowest estimate is $41.3M.
A total of 6 analysts have provided revenue estimates for DNA’s current fiscal year. The highest revenue estimate was $180M, while the lowest revenue estimate was $170.97M, resulting in an average revenue estimate of $175.51M. In the same quarter a year ago, actual revenue was $227.04MBased on 6 analysts’ estimates, the company’s revenue will be $197.05M in the next fiscal year. The high estimate is $220.01M and the low estimate is $171.56M.
